These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6896784)

  • 1. [Lymphoid interstitial pneumonia. Presentation of 2 cases with follow-up].
    Verhamme M; Wynants P; Van de Woestijne KP; Lauweryns J
    Acta Clin Belg; 1982; 37(2):65-71. PubMed ID: 6896784
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide therapy and interstitial pulmonary fibrosis.
    Patel AR; Shah PC; Rhee HL; Sassoon H; Rao KP
    Cancer; 1976 Oct; 38(4):1542-9. PubMed ID: 1068740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP.
    Deau B; Franchi P; Briere J; Ohnona J; Tamburini J; Thieblemont C; Brice P
    Br J Haematol; 2015 Jul; 170(2):278-81. PubMed ID: 25580881
    [No Abstract]   [Full Text] [Related]  

  • 4. [The practice of chemotherapy with the DeVita protocol].
    Gassmann W; Schmitz N; Löffler H
    Dtsch Med Wochenschr; 1982 Jul; 107(27):1063-9. PubMed ID: 6177488
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):9-10. PubMed ID: 27007004
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotropic large cell lymphoma presenting as interstitial lung disease.
    Tan TB; Spaander PJ; Blaisse M; Gerritzen FM
    Thorax; 1988 Jul; 43(7):578-9. PubMed ID: 3212758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone.
    Meuret G; Fueter R; Gloor F
    Respiration; 1978; 36(4):228-33. PubMed ID: 674871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
    Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lung infiltrations in Hodgkin lymphoma].
    Ciurea-Löchel A; Ciurea A; Stey C; Pestalozzi B
    Praxis (Bern 1994); 2001 Aug; 90(31-32):1307-11. PubMed ID: 11519195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.
    Sagar TG; Chandra A; Raman SG
    Med Pediatr Oncol; 2003 Jan; 40(1):66-9. PubMed ID: 12426693
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: a Southwest Oncology Group Phase II Study.
    Miller TP; Jones SE; Rainey JM
    Cancer Treat Rep; 1983; 67(7-8):739-40. PubMed ID: 6688200
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.
    Klumb CE; Carriço MK; de Rezende LM; Byington R; Bordallo MA; Bigni RS; Apa AG; Dobbin JA
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):628-9. PubMed ID: 17662581
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
    Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
    Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
    [No Abstract]   [Full Text] [Related]  

  • 15. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug therapy of malignant lymphoma].
    Ogawa M; Inagaki J
    Rinsho Hoshasen; 1985 Oct; 30(11):1317-32. PubMed ID: 2418229
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant histiocytosis. Case report and review.
    Marshall ME
    J Ky Med Assoc; 1983 Jan; 81(1):18-23. PubMed ID: 6687475
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolymphocytic leukemia. Serial responses to therapy.
    Swift JF; Wold HG; Gandara DR; Redmond J; George CB
    Cancer; 1984 Sep; 54(6):978-80. PubMed ID: 6590113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary lymphoblastic lymphoma of the breast.
    Carbone A; Volpe R; Tirelli U; Veronesi A; Galligioni E; Trovo MG; Grigoletto E
    Clin Oncol; 1982 Dec; 8(4):367-73. PubMed ID: 6897770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.